ARCA Biopharma Inc ABIO:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 1:26 PM EST
4.65quote price arrow up+0.28 (+6.41%)
Volume
1,928,427
52 week range
2.21 - 22.00

...

Loading . . .

KEY STATS

  • Open4.41
  • Day High4.80
  • Day Low4.33
  • Prev Close4.37
  • 52 Week High22.00
  • 52 Week High Date05/28/20
  • 52 Week Low2.21
  • 52 Week Low Date03/19/20
  • Market Cap43.34M
  • Shares Out9.32M
  • 10 Day Average Volume1.58M
  • Dividend-
  • Dividend Yield-
  • Beta2.84
  • 1 Year % Change22.91

RATIOS/PROFITABILITY

  • EPS (TTM)-2.65
  • P/E (TTM)-1.75
  • Fwd P/E (NTM)-0.51
  • EBITDA (MRQ)-5.91M
  • ROE (MRQ)-19.71%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest ARCA Biopharma Inc News

There is no recent news for this security.

Latest ABIO News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is...
Robert Conway CPA
Chairman
Michael Bristow M.D., Ph.D.
Chief Executive Officer
Thomas Keuer
Chief Operating Officer
Brian Selby CPA
Chief Accounting Officer
Address
10170 Church Ranch Way, Suite 100
Westminster, CO
80021
United States